Bortezomib will boost the stage or impact of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Increased flibanserin adverse results may arise if coadministered with numerous weak CYP3A4 inhibitors. Unlock 38% far more drug discovery time and reduce final decision-building uncertainties using this one particular-cease guidebook to excellent drug https://robertj555whs8.mywikiparty.com/user